UNSPSC 51121923: Nepicastat

This classification denotes an enzyme inhibitor with the molecular formula C14H15F2N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPG12K4540, chemically known as 5-(aminomethyl)-1-((s)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl)-4-imidazoline-2-thione but generally known as nepicastat, which bears US NIH Compound Identifier 6367078. European Medicines Agency schedules Nepicastat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09199MIG.

UNSPSC 51121923 Nepicastat, a Commodity code, identifies prescription pharmaceuticals and medications that state and local governments procure for emergency medical services, public health programs, and institutional healthcare delivery. Recent solicitations show state and local buyers acquiring specific emergency life support medications, generic multi-source pharmaceuticals distributed through cooperative purchasing networks, and direct-to-manufacturer prescription programs designed to improve cost management and fulfillment efficiency across government health plans and employee benefit programs.

State and local governments soliciting under this code include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department recently solicited sealed bids for Advanced Life Support Medications (Bid No. 26-P-00188) due April 8, 2026, requiring vendors to supply Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year term renewable for two additional years. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) across participating state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) with a response deadline of April 3, 2026, to gather vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program supporting direct contracting between state pharmacy benefit programs and manufacturers outside traditional PBM and GPO channels. Recent activity spans Florida, Minnesota, Oregon, and Texas, with both emergency-use medications for public safety agencies and broader multi-source pharmaceutical procurement through state cooperative purchasing vehicles.